Cargando…

Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography

Neurokinin 1 receptor (NK1R) has key regulating functions in the central and peripheral nervous systems, and NK1R antagonists such as aprepitant have been approved for treating chemotherapy-induced nausea and vomiting. However, the lack of data on NK1R structure and biochemistry has limited further...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shuanghong, Lu, Mengjie, Liu, Dongsheng, Yang, Lingyun, Yi, Cuiying, Ma, Limin, Zhang, Hui, Liu, Qing, Frimurer, Thomas M., Wang, Ming-Wei, Schwartz, Thue W., Stevens, Raymond C., Wu, Beili, Wüthrich, Kurt, Zhao, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367319/
https://www.ncbi.nlm.nih.gov/pubmed/30733446
http://dx.doi.org/10.1038/s41467-019-08568-5
_version_ 1783393764501356544
author Chen, Shuanghong
Lu, Mengjie
Liu, Dongsheng
Yang, Lingyun
Yi, Cuiying
Ma, Limin
Zhang, Hui
Liu, Qing
Frimurer, Thomas M.
Wang, Ming-Wei
Schwartz, Thue W.
Stevens, Raymond C.
Wu, Beili
Wüthrich, Kurt
Zhao, Qiang
author_facet Chen, Shuanghong
Lu, Mengjie
Liu, Dongsheng
Yang, Lingyun
Yi, Cuiying
Ma, Limin
Zhang, Hui
Liu, Qing
Frimurer, Thomas M.
Wang, Ming-Wei
Schwartz, Thue W.
Stevens, Raymond C.
Wu, Beili
Wüthrich, Kurt
Zhao, Qiang
author_sort Chen, Shuanghong
collection PubMed
description Neurokinin 1 receptor (NK1R) has key regulating functions in the central and peripheral nervous systems, and NK1R antagonists such as aprepitant have been approved for treating chemotherapy-induced nausea and vomiting. However, the lack of data on NK1R structure and biochemistry has limited further drug development targeting this receptor. Here, we combine NMR spectroscopy and X-ray crystallography to provide dynamic and static characterisation of the binding mode of aprepitant in complexes with human NK1R variants. (19)F-NMR showed a slow off-rate in the binding site, where aprepitant occupies multiple substates that exchange with frequencies in the millisecond range. The environment of the bound ligand is affected by the amino acid in position 2.50, which plays a key role in ligand binding and receptor signaling in class A GPCRs. Crystal structures now reveal how receptor signaling relates to the conformation of the conserved NP(7.50)xxY motif in transmembrane helix VII.
format Online
Article
Text
id pubmed-6367319
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-63673192019-02-11 Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography Chen, Shuanghong Lu, Mengjie Liu, Dongsheng Yang, Lingyun Yi, Cuiying Ma, Limin Zhang, Hui Liu, Qing Frimurer, Thomas M. Wang, Ming-Wei Schwartz, Thue W. Stevens, Raymond C. Wu, Beili Wüthrich, Kurt Zhao, Qiang Nat Commun Article Neurokinin 1 receptor (NK1R) has key regulating functions in the central and peripheral nervous systems, and NK1R antagonists such as aprepitant have been approved for treating chemotherapy-induced nausea and vomiting. However, the lack of data on NK1R structure and biochemistry has limited further drug development targeting this receptor. Here, we combine NMR spectroscopy and X-ray crystallography to provide dynamic and static characterisation of the binding mode of aprepitant in complexes with human NK1R variants. (19)F-NMR showed a slow off-rate in the binding site, where aprepitant occupies multiple substates that exchange with frequencies in the millisecond range. The environment of the bound ligand is affected by the amino acid in position 2.50, which plays a key role in ligand binding and receptor signaling in class A GPCRs. Crystal structures now reveal how receptor signaling relates to the conformation of the conserved NP(7.50)xxY motif in transmembrane helix VII. Nature Publishing Group UK 2019-02-07 /pmc/articles/PMC6367319/ /pubmed/30733446 http://dx.doi.org/10.1038/s41467-019-08568-5 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Chen, Shuanghong
Lu, Mengjie
Liu, Dongsheng
Yang, Lingyun
Yi, Cuiying
Ma, Limin
Zhang, Hui
Liu, Qing
Frimurer, Thomas M.
Wang, Ming-Wei
Schwartz, Thue W.
Stevens, Raymond C.
Wu, Beili
Wüthrich, Kurt
Zhao, Qiang
Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_full Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_fullStr Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_full_unstemmed Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_short Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography
title_sort human substance p receptor binding mode of the antagonist drug aprepitant by nmr and crystallography
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367319/
https://www.ncbi.nlm.nih.gov/pubmed/30733446
http://dx.doi.org/10.1038/s41467-019-08568-5
work_keys_str_mv AT chenshuanghong humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT lumengjie humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT liudongsheng humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT yanglingyun humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT yicuiying humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT malimin humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT zhanghui humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT liuqing humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT frimurerthomasm humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT wangmingwei humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT schwartzthuew humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT stevensraymondc humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT wubeili humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT wuthrichkurt humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography
AT zhaoqiang humansubstancepreceptorbindingmodeoftheantagonistdrugaprepitantbynmrandcrystallography